Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | KEAP1 loss |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| KEAP1 loss | lung adenocarcinoma | sensitive | Buthionine sulfoximine + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, Buthionine sulfoximine (BSO) increased sensitivity of KEAP1 knockout non-small cell lung cancer cells to radiotherapy in culture (PMID: 33071215). | 33071215 | |
| KEAP1 loss | lung adenocarcinoma | sensitive | Radiotherapy + Telaglenastat | Preclinical - Cell culture | Actionable | In a preclinical study, Telaglenstat (CB-839) increased sensitivity of KEAP1 knockout non-small cell lung cancer cells to radiotherapy in culture, demonstrating increased cell death and DNA double-strand breaks (PMID: 33071215). | 33071215 |